

Semantic Models for CDISC Based Standards and Metadata Management

Frederik Malfait, IMOS Consulting

Information Architect

Data Standards, PD Biometrics, Hoffmann-La Roche


Roche Data Standards Office

Remit and Scope

- Design and manage end-to-end data standards, from protocol to submission, with supporting business processes
- Define data standards for use with gRED, pRED, and PD clinical trial data
- Drive adoption of current & future industry standards (CDISC)
- Provide lifecycle management and governance for all data standards
- Coordinate contributions to external standards bodies

Global Data Standards Integration Initiative


Status at time of Roche-Genentech integration



Global Data Standards Integration Initiative

Timelines


2010



Define
 Review
 Arbitration/Approval

Global Data Standards Repository (GDSR)

What is in there?



Global Data Standards Repository

Content Requirements

- End-to-End **data standards** from protocol to submission cover the complete life cycle of clinical research data
 - Protocol Design
 - **Data Collection**
 - **Data Tabulation** } **Current Scope**
 - Data Analysis
 - Regulatory Submission
- Based on **CDISC Industry Standards**
- Objective
 - Support **consistent definition**, management, and processing of clinical research data throughout all stages of the life cycle
 - Support **data standards management**

Global Data Standards Repository

Content Elements

- Standards for data collection
 - CRF logical structure, design, layout
 - CRF fields, forms, help text, completion guidelines, annotations
- Standards for data tabulation
 - CDISC SDTM 1.2, SDTMIG 3.1.2, Controlled Terminology
 - Sponsor defined extensions
- Standards for data analysis
 - Specification of derived data elements
- Standards for consistent definitions
 - Associate data elements with defined concepts
 - Versioning and life cycle management


Global Data Standards

Wide Variety of Content Types

- CDISC versus sponsor defined standards
- Collected versus tabulated versus analysis data structures
- Value Level Metadata
 - Controlled Terminology
 - Lab Metadata
 - Questionnaires
- External references, e.g. NCI Thesaurus
- Sources available in Word, Excel, PDF, XML formats
- Administrative metadata, e.g. versioning and life cycle information

Global Data Standards Repository (GDSR)

How does it look like?



GDSR Modeling

Objectives

- Develop a meta-model to capture and interconnect
 - Common Conceptual Domain Model
 - Data Standard Models
 - Value Level Metadata
- Represent all output of the standardization effort as structured information
 - Avoid implicit information in documents
- Capture this information in an electronic repository called the Global Data Standards Repository (GDSR)

GDSR Modeling

Technology

- Candidate meta-models
 - Relational meta-data model
 - UML object-oriented model
 - Semantic model


- Advantages of semantic models and ontology frameworks
 - Easy to federate disparate types of data and meta-data (Linked Data)
 - Ontologies are increasingly based on the OWL format (e.g. NCI Thesaurus)
 - Prepare readiness to adopt the CDISC BRIDG model and SHARE repository

- Standards and Tools
 - Mature W3C standards (URI, XML, RDF, RDFS, OWL, SPARQL)
 - Availability of mature semantic modeling tools

Semantic Modeling


1. RDF Graphs

Directed Graph of Subject - Predicate - Object Triples



Semantic Modeling

2. Content and Schema



Everything is a Triple

Semantic Modeling

3. *Uniform Resource Identifiers*

- In RDF everything is a triple (content and schema)
- A triple is either a <Subject Predicate Object> or a <Subject Predicate Value>
- Subjects, predicates, and objects are commonly called RDF resources
- Every RDF resource has a Uniform Resource Identifier (URI)
- Namespaces provide a convenient way to group related resources together

Uniform Resource Identifiers

Example

- Global Data Standards Repository
 - The resource representing the SDTM domain AE (Adverse Events)
<http://gdsr.roche.com/cdisc/sdtmig-3-1-2#Table.AE>
 - The prefix sdtmig identifies the namespace
<http://gdsr.roche.com/cdisc/sdtmig-3-1-2#>
 - The qualified name for the same resource
[sdtmig:Table.AE](#)
- Examples from the W3C standards
 - rdf:type is the qualified name of
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>
 - owl:Class is the qualified name of
<http://www.w3.org/2002/07/owl#Class>

Semantic Modeling

4. Inference

- RDFS and OWL provide a set of predicates for schema modeling
 - e.g. owl:inverseOf relates two inverse properties
<hasCitizen owl:inverseOf livesIn>
- Its meaning is defined by the way new triples may be derived from existing triples
 - Stated Triple
<Jon livesIn Basel>
 - Derived Triple
<Basel hasCitizen Jon>

Web Ontology Language (OWL)

Predicates

- owl:allValuesFrom
- owl:annotatedProperty
- owl:annotatedSource
- owl:annotatedTarget
- owl:assertionProperty
- owl:backwardCompatibleWith
- owl:bottomDataProperty
- owl:bottomObjectProperty
- owl:cardinality
- owl:complementOf
- owl:datatypeComplementOf
- owl:deprecated
- owl:differentFrom
- owl:disjointUnionOf
- owl:disjointWith
- owl:distinctMembers
- owl:equivalentClass
- owl:equivalentProperty
- owl:hasKey
- owl:hasSelf
- owl:hasValue
- owl:imports
- owl:incompatibleWith
- owl:intersectionOf
- owl:inverseOf
- owl:maxCardinality
- owl:maxQualifiedCardinality
- owl:members
- owl:minCardinality
- owl:minQualifiedCardinality
- owl:onClass
- owl:onDataRange
- owl:onDatatype
- owl:oneOf
- owl:onProperties
- owl:onProperty
- owl:priorVersion
- owl:propertyChainAxiom
- owl:propertyDisjointWith
- owl:qualifiedCardinality
- owl:sameAs
- owl:someValuesFrom
- owl:sourceIndividual
- owl:targetIndividual
- owl:targetValue
- owl:topDataProperty
- owl:topObjectProperty
- owl:unionOf
- owl:versionInfo
- owl:versionIRI
- owl:withRestrictions

Semantic Modeling

W3C Standards


- Resource Description Framework (RDF)
 - RDF defines how to express a knowledge base (content) as a directed graph of resources (set of triples)
 - Every resource has a URI and is part of a namespace
- RDF Schema (RDFS) and Web Ontology Language (OWL)
 - A set of standard predicates to build vocabularies (schemas)
 - Inference capabilities
- SPARQL Protocol and RDF Query Language (SPARQL)
 - Language to query an RDF knowledge base
- Simple Knowledge Organization System (SKOS)
 - Small footprint RDF based schema for concept models

Linked Data

Content Federation

- Semantic models in RDF format are easy to federate
- Federation of Data = Union of Triples (from both graphs)
- Use `owl:sameAs` to specify that two resources are equal

Federated Graph




Linked Data


dbpedia.org

The DBpedia knowledge base currently describes more than 3.5 million things, out of which 1.67 million are classified in a consistent Ontology, including 364,000 persons, 462,000 places, 99,000 music albums, 54,000 films, 17,000 video games, 148,000 organisations, 169,000 species and 5,200 diseases.

The DBpedia data set features labels and abstracts for these 3.5 million things in up to 97 different languages; 1,850,000 links to images and 5,900,000 links to external web pages; 6,500,000 external links into other RDF datasets, 633,000 Wikipedia categories, and 2,900,000 YAGO categories. The DBpedia knowledge base altogether consists of over 672 million pieces of information (RDF triples) out of which 286 million were extracted from the English edition of Wikipedia and 386 million were extracted from other language editions.





Linked Open Data




Global Data Standards Repository

Semantic Information Model



Global Data Standards Repository (GDSR)

What can we do with it?





GDSR Applications

Objectives


- Provide access to the GDSR
 - As input to other systems for machine consumption
 - As a knowledge source for human consumption

Global Data Standards Repository


UML Deployment Diagram



Content Management



Content Publishing



Metadata Repository



Single Point of Access

TopBraid Semantic Modeling Workbench

- ▲ 📁 > Global Data Standards Repository, Trunk
 - ▷ 📁 .settings
 - ▷ 📁 export-files 725
 - ▲ 📁 > gdsr.roche.com 728
 - ▲ 📁 cdisc 716
 - 📄 adam-terminology-schema.owl 217 [http://gdsr.roche.com/cdisc/adam-terminology-schema]
 - 📄 adam-terminology.owl 671 [http://gdsr.roche.com/cdisc/adam-terminology]
 - 📄 cdash-terminology-schema.owl 217 [http://gdsr.roche.com/cdisc/cdash-terminology-schema]
 - 📄 cdash-terminology.owl 671 [http://gdsr.roche.com/cdisc/cdash-terminology]
 - 📄 sdtm-1-2-schema.diagrams 220
 - 📄 sdtm-1-2-schema.owl 220 [http://gdsr.roche.com/cdisc/sdtm-1-2-schema]
 - 📄 sdtm-1-2.owl 642 [http://gdsr.roche.com/cdisc/sdtm-1-2]
 - 📄 sdtm-terminology-schema.diagrams 166
 - 📄 sdtm-terminology-schema.owl 217 [http://gdsr.roche.com/cdisc/sdtm-terminology-schema]
 - 📄 sdtm-terminology.owl 671 [http://gdsr.roche.com/cdisc/sdtm-terminology]
 - 📄 sdtmig-3-1-2-schema.diagrams 715
 - 📄 sdtmig-3-1-2-schema.owl 715 [http://gdsr.roche.com/cdisc/sdtmig-3-1-2-schema]
 - 📄 sdtmig-3-1-2.owl 716 [http://gdsr.roche.com/cdisc/sdtmig-3-1-2]
 - ▷ 📁 common 691
 - ▲ 📁 > pd-biometrics 728
 - 📄 all-standards.owl 647 [http://gdsr.roche.com/pd-biometrics/all-standards]
 - 📄 clinical-finding.owl 706 [http://gdsr.roche.com/pd-biometrics/clinical-finding]
 - 📄 data-analysis-schema.diagrams 287
 - 📄 data-analysis-schema.owl 287 [http://gdsr.roche.com/pd-biometrics/data-analysis-schema]
 - 📄 data-analysis.owl 272 [http://gdsr.roche.com/pd-biometrics/data-analysis]
 - 📄 data-collection-schema.diagrams 392
 - 📄 data-collection-schema.owl 392 [http://gdsr.roche.com/pd-biometrics/data-collection-schema]
 - 📄 data-collection.owl 771 [http://gdsr.roche.com/pd-biometrics/data-collection]
 - 📄 diagnostic-procedure.owl 645 [http://gdsr.roche.com/pd-biometrics/diagnostic-procedure]
 - 📄 findings-schema.diagrams 231
 - 📄 findings-schema.owl 231 [http://gdsr.roche.com/pd-biometrics/findings-schema]
 - 📄 findings.owl 186 [http://gdsr.roche.com/pd-biometrics/findings]
 - 📄 lab-metadata.owl 698 [http://gdsr.roche.com/pd-biometrics/lab-metadata]
 - 📄 > questionnaire.owl 775 [http://gdsr.roche.com/pd-biometrics/questionnaire]
 - 📄 rave-schema.diagrams 216

Class Form



URI: OK

Annotations

rdfs:isDefinedBy

rdfs:label

skos:definition

The Events class captures planned protocol milestones such as randomization and study completion, and occurrences, conditions, or incidents independent of planned study evaluations occurring during the trial (e.g., adverse events) or prior to the trial (e.g., medical history).

Other Properties

rdf:type

Class Axioms

rdfs:subClassOf

Form | Diagram | Graph | Form Layout | Source Code

Instances



| [Resource] | rdfs:label | rdfs:comment |
|------------|------------|--------------|
| Table.AE | | |
| Table.CE | | |
| Table.DS | | |
| Table.DV | | |
| Table.MH | | |

Resource Form



URI:

OK

Annotations

Incoming References

← mms:dataElementDomain ▾

- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾
- ◆ ▾

Other Properties

sdtmigs:domainCode ▾

sdtmigs:domainStructure ▾

mms:domainLabel ▾

mms:domainName ▾

mms:domainOrdinal ▾

mdr:administrationRecord ▾

◆

mdr:context ▾

◆

rdf:type ▾

●

Resource Form



URI: <http://gdsr.roche.com/cdisc/sdtmig-3-1-2#Column.AE.AEOUT>

Ok

▼ Annotations

▼ Incoming References

▼ Other Properties

sdtms:dataElementCompliance ▼

◆ sdtms:Classifier.PermissibleVariable ▼

sdtms:dataElementRole ▼

◆ sdtms:Classifier.RecordQualifier ▼

sdtms:dataElementType ▼

◆ sdtms:Classifier.Char ▼

sdtmigs:controlledTermsOrFormat ▼

S (OUT) ▼

sdtmigs:dataElementCodelist ▼

◆ sdtmt:C66768 ▼

sdtmigs:references ▼

S SDTM 2.2.2 ▼

mms:dataElement ▼

◆ sdtm:DE.Event.--OUT ▼

mms:dataElementDescription ▼

S Description of the outcome of an event. ▼

mms:dataElementDomain ▼

◆ Table.AE ▼

mms:dataElementLabel ▼

S Outcome of Adverse Event ▼

mms:dataElementName ▼

S AEOUT ▼

Resource Form



URI: OK

Annotations

Incoming References

← sdtmts:parentCodelist ▾

-  ▾
-  ▾
-  ▾
-  ▾
-  ▾
-  ▾

← sdtmigs:dataElementCodelist ▾

-  ▾

Other Properties


sdtmts:cdiscDefinition ▾

 ▾


sdtmts:cdiscSubmissionValue ▾

 ▾


sdtmts:cdiscSynonyms ▾

 ▾


sdtmts:codelistName ▾

 ▾


sdtmts:isExtensibleCodelist ▾

 ▾

sdtmts:nciCode ▾

 ▾

sdtmts:nciPreferredTerm ▾

 ▾

rdf:type ▾

 ▾

Resource Form



URI:


OK

▼ Annotations


▼ Incoming References

▼ Other Properties

sdtmts:cdiscDefinition ▼

 One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated. (NCI) ▼


sdtmts:cdiscSubmissionValue ▼

 NOT RECOVERED/NOT RESOLVED ▼

sdtmts:nciCode ▼

 C49494 ▼

sdtmts:nciPreferredTerm ▼

 Not Recovered or Not Resolved ▼

sdtmts:parentCodelist ▼

 sdtmt:C66768 ▼

rdf:type ▼

 sdtmts:CodelistElement ▼

Resource Form



URI: <http://gdsr.roche.com/cdisc/sdtmig-3-1-2#Column.AE.AEOUT> Ok

▼ Annotations

▼ Incoming References

▼ Other Properties

sdtms:dataElementCompliance ▼

◆ sdtms:Classifier.PermissibleVariable ▼

sdtms:dataElementRole ▼

◆ sdtms:Classifier.RecordQualifier ▼

sdtms:dataElementType ▼

◆ sdtms:Classifier.Char ▼

sdtmigs:controlledTermsOrFormat ▼

S (OUT) ▼

sdtmigs:dataElementCodelist ▼

◆ sdtmt:C66768 ▼

sdtmigs:references ▼

S SDTM 2.2.2 ▼

mms:dataElement ▼

◆ sdtm:DE.Event.--OUT ▼

mms:dataElementDescription ▼

S Description of the outcome of an event. ▼

mms:dataElementDomain ▼

◆ Table.AE ▼

mms:dataElementLabel ▼

S Outcome of Adverse Event ▼

mms:dataElementName ▼

S AEOUT ▼

Resource Form



URI:

OK

Annotations

rdfs:isDefinedBy

rdfs:label

skos:definition

Other Properties

rdf:type

Incoming References

←

- Column.AE.AEACNOTH
- Column.AE.AECAT
- Column.AE.AECONTRT
- Column.AE.AEDUR
- Column.AE.AEENDY
- Column.AE.AEENRF
- Column.AE.AEENRTPT
- Column.AE.AEENTPT

Hoffmann-La Roche

Global Data Standards Browser

Data Tabulation

[Administration Panel](#)

- SDTM 3.1.2 Extended
 - + General Observations
 - + Special Purpose Class
- Controlled Terminology
 - + CDISC Terminology
 - + Sponsor Terminology
- Value Level Metadata
 - + Findings Metadata for Measurements
 - + Questionnaires
 - + Clinical Findings
 - + Diagnostic Procedures

Please select an item.

- SDTM 3.1.2 Extended
 - General Observations
 - **Events Observation Class**
 - + MH - Medical History
 - + AE - Adverse Events
 - + CE - Clinical Events
 - + DV - Protocol Deviations
 - + DS - Disposition
 - + YI - Site and Investigator
 - + Findings Observation Class
 - + Interventions Observation Class
 - + Special Purpose Class
- Controlled Terminology
 - + CDISC Terminology
 - + Sponsor Terminology
- Value Level Metadata
 - + Findings Metadata for Measurements
 - + Questionnaires
 - + Clinical Findings
 - + Diagnostic Procedures

Events Observation Class

The Events class captures planned protocol milestones such as randomization and study completion, and occurrences, conditions, or incidents independent of planned study evaluations occurring during the trial (e.g., adverse events) or prior to the trial (e.g., medical history).

- SDTM 3.1.2 Extended
 - General Observations
 - Events Observation Class
 - + MH - Medical History
 - + AE - Adverse Events**
 - + CE - Clinical Events
 - + DV - Protocol Deviations
 - + DS - Disposition
 - + YI - Site and Investigator
 - + Findings Observation Class
 - + Interventions Observation Class
 - + Special Purpose Class
- Controlled Terminology
 - + CDISC Terminology
 - + Sponsor Terminology
- Value Level Metadata
 - + Findings Metadata for Measurements
 - + Questionnaires
 - + Clinical Findings
 - + Diagnostic Procedures

[< back](#) **AE - Adverse Events**

Showing 1 to 50 of 67 Show 50 | [All](#)

[<<](#) [<](#) [1](#) [2](#) [>](#) [>>](#)

| Name | Label | Type | Role | Core |
|--------------------------|-------------------------------------|----------------------|----------------------|----------------------|
| STUDYID | Study Identifier | Char 8 String | Identifier Variable | Required Variable |
| DOMAIN | Domain Abbreviation | Char 2 String | Identifier Variable | Required Variable |
| USUBJID | Unique Subject Identifier | Char 50 String | Identifier Variable | Required Variable |
| AESEQ | Sequence Number | Num 8 Decimal | Identifier Variable | Required Variable |
| AEGRPID | Group ID | Char 40 String | Identifier Variable | Permissible Variable |
| AEREFID | Reference ID | Char 40 String | Identifier Variable | Permissible Variable |
| AESPID | Sponsor-Defined Identifier | Char 200 String | Identifier Variable | Permissible Variable |
| AETERM | Reported Term for the Adverse Event | Char 200 String | Topic Variable | Required Variable |
| AEMODIFY | Modified Reported Term | Char 200 String | Synonym Qualifier | Permissible Variable |

- SDTM 3.1.2 Extended
 - General Observations
 - Events Observation Class
 - + MH - Medical History
 - AE - Adverse Events
 - AESPID - Sponsor-Defined Identifier
 - AESER - Serious Event
 - AEENDY - Study Day of End of Adverse Event
 - AETOXGR - Standard Toxicity Grade
 - AESOD - Occurred with Overdose
 - AESTDTC - Start Date/Time of Adverse Event
 - AESLIFE - Is Life Threatening
 - AEMODIFY - Modified Reported Term
 - DOMAIN - Domain Abbreviation
 - AEENRTPT - End Relative to Reference Time Point
 - AEPRESP - Pre-Specified Adverse Event
 - AEENRF - End Relative to Reference Period
 - STUDYID - Study Identifier
 - AEPATT - Pattern of Adverse Event
 - AESCONG - Congenital Anomaly or Birth Defect
 - AESTDY - Study Day of Start of Adverse Event
 - AECAT - Category for Adverse Event

[< back](#)

AEOUT - Outcome of Adverse Event

| | |
|------------------|----------------------------------|
| Name | AEOUT |
| Label | AEOUT - Outcome of Adverse Event |
| Type | Char 40 String T |
| Role | Record Qualifier |
| Core | Permissible Variable |
| Suppqual Repeats | |

CDISC Notes

Description of the outcome of an event.

Sponsor Notes

AEOUT is the Outcome of the adverse event represented using CDISC controlled terminology.

- + SDTM 3.1.2 Extended
- Controlled Terminology
 - CDISC Terminology
 - C65047 Laboratory Test Code
 - C66726 Pharmaceutical Dosage Form
 - C66727 Completion/Reason for Not Completing
 - C66728 Relation to Reference Period
 - C66729 Route of Administration
 - C66731 Sex
 - C66732 Sex of Participants
 - C66733 Size
 - C66734 Domain Abbreviation
 - C66735 Trial Blinding Schema
 - C66736 Trial Indication Type
 - C66737 Trial Phase
 - C66738 Trial Summary Parameter
 - C66739 Trial Type
 - C66741 Vital Signs Test Code
 - C66742 No Yes Response
 - C66767 Action Taken with Study Treatment
 - ✓ C66768 Outcome of Event**
 - C66769 Severity/Intensity Scale for Adverse Event
 - C66770 Units for Vital Signs Result
 - C66780 Age Span
 - C66781 Age Unit
 - C66783 CDISC System Organ Classification
 - C66784 Common Terminology Criteria Code
 - C66785 Control Type
 - C66786 Country
 - C66787 Diagnosis Group
 - C66788 Disposition

[← back](#) **Controlled Terminology**

| | |
|------------------------|--|
| Codelist Publisher | CDISC |
| NCI Code | C66768 |
| Codelist is Extensible | No |
| Codelist Name | Outcome of Event |
| CDISC Definition | A condition or event that is attributed to the adverse event and is the result or conclusion of the adverse event. (NCI) |

CDISC Codelist

Showing 1 to 6 of 6 Show 50 | [All](#) << < 1 > >>

| ▲ NCI Code | ◆ CDISC Submission Value | ◆ CDISC Definition | ◆ CDISC Synonym(s) | ◆ NCI Preferred Term |
|----------------------------|--|--|------------------------------------|--------------------------------------|
| C17998 | UNKNOWN | Not known, not observed, not recorded, or refused. (NCI) | U; Unknown | Unknown |
| C48275 | FATAL | The termination of life as a result of an adverse event. (NCI) | Grade 5; 5 | Death Related to Adverse Event |
| C49494 | NOT RECOVERED/NOT RESOLVED | One of the possible results of an adverse event outcome that | | Not Recovered or Not Resolved |

- SDTM 3.1.2 Extended
 - + General Observations
 - + Special Purpose Class
- Controlled Terminology
 - + CDISC Terminology
 - + Sponsor Terminology
- Value Level Metadata
 - Findings Metadata for Measurements
 - **Measurements**
 - Chemistry
 - Coagulation
 - Flow Cytometry
 - Genomics
 - Hematology**
 - Immunology
 - Microbiology
 - Other
 - Pharmacology
 - Serology
 - Urinalysis
 - Urine Drug Screen
 - Virology
 - Unit Synonyms
 - Unit Conversions

[back](#) **Hematology Measurements**

Showing 1 to 50 of 215 Show 50 | [All](#)

<< < 1 2 3 4 5 > >>

| Name | Label | Domain | --TEST | --TESTCD |
|----------------------|--------------------------------|------------------------|----------------------------------|--------------------------|
| ABS_NEUT_COUNT | Absolute Neutrophil Count | LB | Neutrophils | NEUT |
| ACANTHOCYTOSIS | RBC Morphology, Acanthocytosis | LB | Acanthocytes | ACANT |
| ALDER_ANOMALY_INCL | Alder Anomaly, Inclusion | LB | Alder's Anomaly | ALDANOM |
| ANISOCYTOSIS | RBC Morphology, Anisocytosis | LB | Anisocytes | ANISO |
| AUER_RODS | WBC Comment, Auer Rods | LB | Auer Rods | AUERRODS |
| BABESIA | Babesia | LB | Babesia | BABE |
| BAND_ABS | Bands, Absolute Count | LB | Neutrophils Band Form | NEUTB |
| BAND_PERCENT | Neutrophils, Bands, Percent | LB | Neutrophils Band Form/Leukocytes | NEUTBLE |

- SDTM 3.1.2 Extended
 - + General Observations
 - + Special Purpose Class
- Controlled Terminology
 - + CDISC Terminology
 - + Sponsor Terminology
- Value Level Metadata
 - + Findings Metadata for Measurements
 - Questionnaires
 - + 5-D Pruritus Scale
 - + Aberrant Behavior Checklist
 - + Abnormal Involuntary Movement Scale
 - + Addiction Research Center Inventory Questionnaire (49 Q)
 - + Alzheimer's Disease Cooperative Study Group - Activities
 - + Anxiety, Depression and Mood Scale
 - + Asthma Control Questionnaire**
 - + Asthma Quality of Life Questionnaire with Standard Activit
 - + Asthma Symptom Utility Index
 - + Autism Diagnostic Observation Schedule Module 2
 - + Autism Diagnostic Observation Schedule Module 3
 - + Autism Diagnostic Observation Schedule Module 4
 - + Beck Depression Inventory - Second Edition
 - + Bond-Lader Visual Analog Scale
 - + Brain Cancer Module Quality of Life Questionnaire
 - + Brief Fatigue Inventory
 - + Brief Pain Inventory (Short Form)
 - + Brief Psychiatric Rating Scale
 - + Calgary Depression Scale for Schizophrenia
 - + Center for Epidemiologic Studies Depression Scale (CES-I)
 - + Chemotherapy Convenience and Satisfaction Questionnai
 - + Children's Depression Inventory 1
 - + Children's Depression Inventory 2

[← back](#)

Asthma Control Questionnaire

| | |
|--------------------------------|--|
| Category (QSCAT) | ACQ |
| Instrument Name | Asthma Control Questionnaire |
| Author | Juniper, Elizabeth, MCSP, Msc |
| Pathology | Immune System Diseases, Respiratory Tract Diseases |
| Therapeutic Area | Inflammation (Asthma) |
| Disease | Asthma |
| Objective | To measure the adequacy of clinical asthma control |
| Patient Reported Outcome (PRO) | Yes |
| Evaluator | |

Showing 1 to 10 of 10 Show 50 | [All](#)

<< < 1 > >>

| ▲ Question Short Name (QSTESTCD) | ◆ Question Name (QSTEST) | ◆ Subcategory (QSSCAT) | ◆ Evaluation Interval (QSEVLINT) | ◆ Question Narrative (QSNAR) |
|--|--|--|--|---|
| QS00201 | Nocturnal Awakenings | SUBJECT | -P1W | On average, during the past week, how often were you woken by your asthma during the night? |
| QS00202 | Morning Symptoms | SUBJECT | -P1W | On average, during the past week, how |

- + SDTM 3.1.2 Extended
- + Controlled Terminology
- Value Level Metadata
 - + Findings Metadata for Measurements
 - Questionnaires
 - + 5-D Pruritus Scale
 - + Aberrant Behavior Checklist
 - + Abnormal Involuntary Movement
 - + Addiction Research Center Inventory
 - + Alzheimer's Disease Cooperative Test
 - + Anxiety, Depression and Mood Scale
 - Asthma Control Questionnaire
 - ✓ **Nocturnal Awakenings**
 - Morning Symptoms
 - Activity Limitation
 - Shortness of Breath
 - Wheeze
 - SABA Usage
 - FEV1 % predicted
 - FEV1 pre-bronchodilator
 - FEV1 predicted
 - FEV1 % predicted
 - Asthma Quality of Life Questionnaire
 - Asthma Symptom Utility Index
 - Autism Diagnostic Observation Schedule
 - Autism Diagnostic Observation Schedule
 - Autism Diagnostic Observation Schedule
 - Beck Depression Inventory - Second Edition
 - Bond-Lader Visual Analog Scale
 - Brain Cancer Module Quality of Life
 - Brief Fatigue Inventory
 - Brief Pain Inventory (Brief Symptom Inventory)

[< back](#) **Nocturnal Awakenings**

| | |
|--------------------------------|---|
| Questionnaire | Asthma Control Questionnaire |
| Section | |
| Question Category (QSCAT) | ACQ |
| Question Short Name (QSTESTCD) | QS00201 |
| Question Name (QSTEST) | Nocturnal Awakenings |
| Subcategory (QSSCAT) | SUBJECT |
| Evaluation Interval (QSEVLINT) | -P1W |
| Question Narrative (QSNAR) | On average, during the past week, how often were you woken by your asthma during the night? |

Showing 1 to 7 of 7 Show 50 | [All](#)

<< < 1 > >>

| ◆ Original Result (QSORRES) | ◆ Original Result Units (QSORRESU) | ◆ Character Result in Standard Format (QSSTRESC) | ◆ Standard Units (QSSTRESU) | ◆ Sponsor Notes |
|---|--|--|---|---------------------------------|
| NEVER | | 0 | | |
| HARDLY EVER | | 1 | | |
| A FEW TIMES | | 2 | | |
| SEVERAL TIMES | | 3 | | |
| MANY TIMES | | 4 | | |

Publishing and Item Level Versioning



[Home](#) > [Administration Panel](#)

Administration Panel

Upload New GDS

Revision

Showing 1 to 20 of 55 Show 20 | [All](#)

<< < 1 2 3 > >>

| GDS revision number | Timestamp | Action | Registrar User ID | As of date | Status | |
|---------------------|----------------------|--------|-------------------|-------------|-------------|------------------------|
| 774 | 12-Apr-2012 11:53:59 | Upload | wilkosm | 12-Apr-2012 | ✓ COMPLETED | Report |
| 777 | 12-Apr-2012 11:26:33 | Upload | wilkosm | 12-Apr-2012 | ✓ COMPLETED | Report |
| 3157 | 11-Apr-2012 17:31:41 | Upload | wilkosm | 11-Apr-2012 | ✓ COMPLETED | Report |
| 3135 | 11-Apr-2012 17:19:02 | Upload | wilkosm | 11-Apr-2012 | ✓ COMPLETED | Report |
| 3157 | 11-Apr-2012 16:15:47 | Upload | wilkosm | 11-Apr-2012 | ✓ COMPLETED | Report |

View items in status Standard as of 19-Apr-2012 [Change](#)



View items in status as of

- Standard
- Proposed
- Candidate
- Standard
- Retired
- Superseded



Using Web Services

Export to SAS Data Sets

| | Question Short Name | Question Name | Category of Question | Subcategory of Question | Evaluation Interval |
|----|---------------------|--|----------------------|-------------------------|---------------------|
| 32 | QS001031 | Disrupts group activities | ABC | HYPERACTIVITY | -P4W |
| 33 | QS001032 | Stays in one position for a long time | ABC | LETHARGY | -P4W |
| 34 | QS001033 | Talks to self loudly | ABC | INAPPROPRIATE SPEECH | -P4W |
| 35 | QS001034 | Cries over minor annoyances or hurts | ABC | IRRITABILITY | -P4W |
| 36 | QS001035 | Repetitive hand, body, or head movements | ABC | STEREOTYPY | -P4W |
| 37 | QS001036 | Mood changes quickly | ABC | IRRITABILITY | -P4W |
| 38 | QS001037 | Unresponsive to structured activities | ABC | LETHARGY | -P4W |
| 39 | QS001038 | Does not stay in seat | ABC | HYPERACTIVITY | -P4W |
| 40 | QS001039 | Won't sit still for any length of time | ABC | HYPERACTIVITY | -P4W |
| 41 | QS001040 | Hard to reach, contact, get through to | ABC | LETHARGY | -P4W |
| 42 | QS001041 | Cries and screams inappropriately | ABC | IRRITABILITY | -P4W |
| 43 | QS001042 | Prefers to be alone | ABC | LETHARGY | -P4W |
| 44 | QS001043 | Does not communicate by words/gestures | ABC | LETHARGY | -P4W |
| 45 | QS001044 | Easily distractible | ABC | HYPERACTIVITY | -P4W |
| 46 | QS001045 | Waves or shakes extremities repeatedly | ABC | STEREOTYPY | -P4W |
| 47 | QS001046 | Repeats a word or phrase over and over | ABC | INAPPROPRIATE SPEECH | -P4W |
| 48 | QS001047 | Stamps feet, bangs objects, slams doors | ABC | IRRITABILITY | -P4W |
| 49 | QS001048 | Constantly runs or jumps around the room | ABC | HYPERACTIVITY | -P4W |
| 50 | QS001049 | Rocks body back and forth repeatedly | ABC | STEREOTYPY | -P4W |
| 51 | QS001050 | Deliberately hurts himself/herself | ABC | IRRITABILITY | -P4W |
| 52 | QS001051 | Pays no attention when spoken to | ABC | HYPERACTIVITY | -P4W |
| 53 | QS001052 | Does physical violence to self | ABC | IRRITABILITY | -P4W |
| 54 | QS001053 | Inactive, never moves spontaneously | ABC | LETHARGY | -P4W |
| 55 | QS001054 | Tends to be excessively active | ABC | HYPERACTIVITY | -P4W |
| 56 | QS001055 | Responds negatively to affection | ABC | LETHARGY | -P4W |
| 57 | QS001056 | Deliberately ignores directions | ABC | HYPERACTIVITY | -P4W |
| 58 | QS001057 | Outbursts/tantrums if not get own way | ABC | IRRITABILITY | -P4W |
| 59 | QS001058 | Shows few social reactions to others | ABC | LETHARGY | -P4W |
| 60 | QS001TS1 | Total Subscale I (Irritability) | ABC | TOTAL | -P4W |
| 61 | QS001TS2 | Total Subscale II (Lethargy) | ABC | TOTAL | -P4W |

Export to Excel Data Tabulation Extract

| | |
|-------------------------|---|
| Owner | Roche PD Biometrics Global Data Standards (GDS) |
| Document | Data Tabulation Standards (DTS) |
| Release Date | 03-04-2012 |
| Status Level | Standard |
| Publication Date | 03-04-2012 |

| | |
|--------------|-----------------------------------|
| Go to | SDTM Domains |
| | Code Lists |
| | Terms |
| | Lab Standards |
| | Preferred Units |
| | Unit Conversions |
| | Questionnaires |
| | Clinical Findings |

| Class | Defined By | Dataset Name | Domain Label |
|---------------------------------|------------|--------------|---------------------------------------|
| Special Purpose Domain | CDISC | DM | Demographics |
| | | CO | Comments |
| | | SE | Subject Elements |
| | | SV | Subject Visits |
| Interventions Observation Class | CDISC | CM | Concomitant Medications |
| | | EX | Exposure |
| | | SU | Substance Use |
| | Sponsor | XM | Meal |
| | | XP | Surgeries and Procedures |
| Events Observation Class | CDISC | AE | Adverse Events |
| | | DS | Disposition |
| | | MH | Medical History |
| | | DV | Protocol Deviations |
| | | CE | Clinical Events |
| | Sponsor | YI | Site and Investigator |
| Findings Observation Class | CDISC | EG | ECG Test Results |
| | | IE | Inclusion/Exclusion Criterion Not Met |
| | | LB | Laboratory Test Results |
| | | PE | Physical Examination |
| | | QS | Questionnaires |

AE

 Adverse Events
 Defined by CDISC
[Events Observation Class](#)

| Name | Label | Type | Length | Format | Codelist | Role | Compliance | CDISC Notes |
|----------|---|------|--------|--------|----------|------------------|----------------------|---|
| AEREL | Causality | Char | 20 | * | | Record Qualifier | Expected Variable | Records the investigator's causality assessment. Do not include NOT RELATED, UNKNOWN, or UNASSIGNED in the future. Check with r |
| AERELNST | Relationship to Non-Study Treatment | Char | 200 | | L00005 | Record Qualifier | Permissible Variable | Records the investigator's relationship to the study drug. May be reported as f |
| AEPATT | Pattern of Adverse Event | Char | 40 | * | L00004 | Record Qualifier | Permissible Variable | Used to indicate the patter |
| AEOUT | Outcome of Adverse Event | Char | 40 | (OUT) | C66768 | Record Qualifier | Permissible Variable | Description of the outcom |
| AESCAN | Involves Cancer | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Was the serious event asso |
| AESCONG | Congenital Anomaly or Birth Defect | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Was the serious event asso |
| AESDISAB | Persist or Signif Disability/Incapacity | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Did the serious event resu |
| AESDTH | Results in Death | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Did the serious event resu |
| AESHOSP | Requires or Prolongs Hospitalization | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Did the serious event requ |
| AESLIFE | Is Life Threatening | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Was the serious event life |
| AESOD | Occurred with Overdose | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Did the serious event occu |
| AESMIE | Other Medically Important Serious Event | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Do additional categories fo |
| AECONTRT | Concomitant or Additional Trtmnt Given | Char | 2 | (NY) | C66742 | Record Qualifier | Permissible Variable | Was another treatment giv |
| AETOXGR | Standard Toxicity Grade | Char | 1 | * | | Record Qualifier | Permissible Variable | Toxicity grade according to v3.0 (CTCAE). Sponsor sho |

| Code List | Label | Extensible | Submission Value | CDISC Definition |
|-----------|--|------------|------------------|---|
| C66735 | Trial Blinding Schema | true | TBLIND | The name of a code list that contains terms to define the type of blinding |
| C66736 | Trial Indication Type | true | TINDTP | The name of a code list that contains terms to define the type of trial, e |
| C66737 | Trial Phase | true | TPHASE | Clinical trials are broken into three or four phases: Phase I tests a new c group; Phase II expands the study to a larger group of people; Phase III group of people to measure whether the treatment actually benefits p its risks; and Phase IV takes place after the drug or treatment has been |
| C66738 | Trial Summary Parameter Test Code | true | TSPARMCD | Individual characteristics of a clinical trial, e.g. description of trial desig objective of trial. (NCI) |
| C66739 | Trial Type | true | TTYPE | The type of clinical trial performed e.g. efficacy, safety. (NCI) |
| C66741 | Vital Signs Test Code | true | VSTESTCD | The name given to the test that analyzes a particular set of vital signs in heart beat (pulse), and blood pressure. (NCI) |
| C66742 | No Yes Response | false | NY | A term that is used to indicate a question with permissible values of ye |
| C66767 | Action Taken with Study Treatment | false | ACN | Action Taken with Study Treatment |
| C66768 | Outcome of Event | false | OUT | A condition or event that is attributed to the adverse event and is the r (NCI) |
| C66769 | Severity/Intensity Scale for Adverse Events | false | AESEV | A scale that defines the degree or state of disease existing in a patient adverse event. (NCI) |
| C66770 | Units for Vital Signs Results | true | VSRESU | The unit used to record and describe the result of a test investigating a |
| C66780 | Age Span | true | AGESPAN | Subgroups of populations based on age. (NCI) |
| C66781 | Age Unit | false | AGEU | Those units of time that are routinely used to express the age of a pers |
| C66783 | CDISC System Organ Class | false | SOC | Terms at the highest level of the CDISC system organ class terminology |
| C66784 | Common Terminology Criteria for Adverse Events | false | TOXGR | A standard terminology developed to report adverse events occurring i terminology criteria for adverse events (CTCAE) are used in study adver New Drug reports to the Food and Drug Administration. The CTCAE cont event term representing the severity of the event. (NCI) |

| Code List | Term | Submission Value | CDISC Definition |
|-----------|--------|----------------------------------|--|
| C66767 | C17998 | UNKNOWN | Not known, not observed, not recorded, or refused. (NCI) |
| C66767 | C48660 | NOT APPLICABLE | Determination of a value is not relevant in the current context. (NCI) |
| C66767 | C49501 | DRUG INTERRUPTED | An indication that a medication schedule was modified by temporarily terminating medication. (NCI) |
| C66767 | C49502 | DRUG WITHDRAWN | An indication that a medication schedule was modified through termination of a medication. (NCI) |
| C66767 | C49503 | DOSE INCREASED | An indication that a medication schedule was modified by addition; either by change in strength or amount. (NCI) |
| C66767 | C49504 | DOSE NOT CHANGED | An indication that a medication schedule was maintained. (NCI) |
| C66767 | C49505 | DOSE REDUCED | An indication that a medication schedule was modified by subtraction, either by change in strength or amount. (NCI) |
| C66768 | C17998 | UNKNOWN | Not known, not observed, not recorded, or refused. (NCI) |
| C66768 | C48275 | FATAL | The termination of life as a result of an adverse event. (NCI) |
| C66768 | C49494 | NOT RECOVERED/NOT RESOLVED | One of the possible results of an adverse event outcome that indicates that the subject did not recuperate. (NCI) |
| C66768 | C49495 | RECOVERED/RESOLVED WITH SEQUELAE | One of the possible results of an adverse event outcome where the subject recuperated with pathological conditions resulting from the prior disease or injury. (NCI) |
| C66768 | C49496 | RECOVERING/RESOLVING | One of the possible results of an adverse event outcome that indicates that the subject is recuperating. (NCI) |
| C66768 | C49498 | RECOVERED/RESOLVED | One of the possible results of an adverse event outcome that indicates that the subject recuperated. (NCI) |
| C66769 | C41338 | MILD | A type of adverse event that is usually transient and may require only minimal medical intervention. The event does not generally interfere with usual activities of daily living. (NCI) |
| C66769 | C41339 | MODERATE | A type of adverse event that is usually alleviated with additional specific therapy. The event interferes with usual activities of daily living, causing discomfort but poses no significant harm to the research participant. (NCI) |
| C66769 | C41340 | SEVERE | A type of adverse event that interrupts usual activities of daily living or significantly interferes with usual activities of daily living, causing discomfort and poses significant harm to the research participant. (NCI) |

Select Category

Go to Measurement Category

| SDTM LBCAT Category | Measurement | SDTM LBTESTCD Test Code | SDTM LBTEST Test Name | SDTM LBSPEC Specimen |
|------------------------|-------------------------------------|----------------------------|---|----------------------------|
| CHEMISTRY | 1, 25-Dihydroxyvitamin D3, Serum | VITD3AT | 1, 25-Dihydroxyvitamin D3 | SERUM |
| | Acid Labile Subunit, Total | ACLABST | Acid Labile Subunit Total | SERUM |
| | Acid Labile Subunit, Total, Recalc. | ACLABSTR | Acid Labile Subunit Total, Recalculated | SERUM |
| | Acid Phosphatase | ACPHOS | Acid Phosphatase | SERUM |
| | Acid Phosphatase, Prostatic | PAP | Prostatic Acid Phosphatase | SERUM |
| | Albumin Index | ALBI | Albumin Index | CEREBROSPINAL FLUID |
| | Albumin Ratio | ALBCSR | Albumin CSF/Serum Ratio | CEREBROSPINAL FLUID, SERUM |
| | Albumin/Globulin Ratio | ALBGLOB | Albumin/Globulin | SERUM |
| | Alk. Phos., Intestine Isoenzym | ALPII | Alkaline Phos, Intestine Isoenzyme | SERUM |
| | Alkaline Phos., Bone Isoenzyme | ALPBI | Alkaline Phosphatase, Bone Isoenzyme | SERUM |
| | Alkaline Phos., Liver Isoenzyme | ALPLI | Alkaline Phosphatase, Liver Isoenzyme | SERUM |
| | Alkaline Phos., Placental Isoenzyme | ALPPI | Alkaline Phosp, Placental Isoenzyme | SERUM |
| | Alkaline Phosphatase | ALP | Alkaline Phosphatase | SERUM |
| | Alkaline Phosphatase, Fractionation | ALPF | Alkaline Phosphatase, Fractionated | SERUM |
| | Alpha Fetoprotein | AFP | Alpha Fetoprotein | SERUM |
| | Alpha-1 Antitrypsin, Serum Conc | A1ANTRYP | Alpha-1 Antitrypsin | SERUM |
| | Alternate Path Complement AH50 | AH50 | AH50 | SERUM |
| | Amylase | AMYLASE | Amylase | SERUM |
| | Apolipoprotein B | APOB | Apolipoprotein B | SERUM |
| | Arterial Blood pH - pH | PH | pH | ARTERIAL BLOOD |
| | Bicarbonate (CO2) | BICARB | Bicarbonate | SERUM |
| | Bilirubin, Direct | BILDIR | Direct Bilirubin | SERUM |

| Instrument | SDTM QSCAT | Author |
|--|--------------|--|
| 5-D Pruritus Scale | 5-D PRURITUS | Elman, S; Hynan, LS; Gabriel, V; Mayo, MJ |
| Aberrant Behavior Checklist | ABC | Slosson Educational Publications, Inc. |
| Abnormal Involuntary Movement Scale | AIMS | |
| Addiction Research Center Inventory Questionnaire (49 Questions) | ARCI-49 | |
| Alzheimer's Disease Cooperative Study Group - Activities of Daily Living | ADCS-ADL | |
| Anxiety, Depression and Mood Scale | ADAMS | |
| Asthma Control Questionnaire | ACQ | Juniper, Elizabeth, MCSP, Msc |
| Asthma Quality of Life Questionnaire with Standard Activities | AQLQ(S) | Juniper, Elizabeth, MCSP, Msc |
| Asthma Symptom Utility Index | ASUI | |
| Autism Diagnostic Observation Schedule Module 2 | ADOS2 | Catherine Lord, Ph.D., Michael Rutter, M.D., FRS, Pamela C. DiLavore, Ph.D., and Susan Risi, Ph.D. |
| Autism Diagnostic Observation Schedule Module 3 | ADOS3 | Catherine Lord, Ph.D., Michael Rutter, M.D., FRS, Pamela C. DiLavore, Ph.D., and Susan Risi, Ph.D. |
| Autism Diagnostic Observation Schedule Module 4 | ADOS4 | Catherine Lord, Ph.D., Michael Rutter, M.D., FRS, Pamela C. DiLavore, Ph.D., and Susan Risi, Ph.D. |
| Beck Depression Inventory - Second Edition | BDI-II | Beck, Aaron T, MD |
| Biphasic Alcohol Effects Scale | BAES | |
| Bond-Lader Visual Analog Scale | BL-VAS | Bond, Alyson; Lader, Malcom |
| Brain Cancer Module Quality of Life Questionnaire | BCM20 | Osoba, D., Aaronson, N.K., Muller, M., Sneeuw, K., Hsu, M.-A., |

Asthma Control Questionnaire

| QSTESTCD | QSTEST | QSEVLINT | Display Text |
|----------|----------------------|----------|--|
| QS00201 | Nocturnal Awakenings | -P1W | On average, during the past week, how often were you woken by your asthma during the night? |
| QS00202 | Morning Symptoms | -P1W | On average, during the past week, how bad were your asthma symptoms when you woke up in the morning? |
| QS00203 | Activity Limitation | -P1W | In general, during the past week, how limited were you in your activities because of your asthma? |

Asthma Control Questionnaire

| QSTESTCD | QSTEST | QSORRES | QSORRESU | QSSTRES |
|----------|----------------------|-----------------------------------|----------|---------|
| QS00201 | Nocturnal Awakenings | NEVER | | 0 |
| | | HARDLY EVER | | 1 |
| | | A FEW TIMES | | 2 |
| | | SEVERAL TIMES | | 3 |
| | | MANY TIMES | | 4 |
| | | A GREAT MANY TIMES | | 5 |
| | | UNABLE TO SLEEP BECAUSE OF ASTHMA | | 6 |
| QS00202 | Morning Symptoms | NO SYMPTOMS | | 0 |
| | | VERY MILD SYMPTOMS | | 1 |
| | | MILD SYMPTOMS | | 2 |
| | | MODERATE SYMPTOMS | | 3 |
| | | QUITE SEVERE SYMPTOMS | | 4 |
| | | SEVERE SYMPTOMS | | 5 |
| | | VERY SEVERE SYMPTOMS | | 6 |
| QS00203 | Activity Limitation | NOT LIMITED AT ALL | | 0 |
| | | VERY SLIGHTLY LIMITED | | 1 |
| | | SLIGHTLY LIMITED | | 2 |

Export to Excel Rave Architect Loader File

- + Safety
- + Across Therapeutic Area
- CNS
 - Alzheimer
 - + Alzheimer Disease History
 - + Modified Hachinski Ischemia Scale
 - **Neurological Exam**
 - Timepoint
 - Was a neurological examination performed?
 - If Yes, date of exam
 - Time of exam
 - Type of neurological examination performed
 - Exam performed?
 - Result
 - Examination category
 - + Schizophrenia
- + Inflammation
- + Metabolism
- + Oncology
- ... Ophthalmology
- + Virology

[< back](#)

Neurological Exam

| | |
|-------------------|---------------------------|
| Form Policy | Study Build Optional Form |
| Form Layout | Mixed Form |
| Study Build Note | |
| Rave GVI Form OID | NE |

Help Text

At the Screening visit, enter any findings/conditions on the General Medical History and Baseline Conditions form. After the screening visit, enter any new or worsened findings/conditions on the Adverse Event form.

SDTM Annotation(s)

Domain: ZA

ZA.ZACAT = 'NEUROLOGICAL EXAMINATION'



- + Safety
- + Across Therapeutic Area
- CNS
 - Alzheimer
 - + Alzheimer Disease History
 - + Modified Hachinski Ischemia Scale
 - Neurological Exam
 - Timepoint
 - Was a neurological examination performed?
 - If Yes, date of exam
 - Time of exam
 - Type of neurological examination performed
 - Exam performed?
 - Result
 - Examination category**
 - + Schizophrenia
- + Inflammation
- + Metabolism
- + Oncology
- Ophthalmology
- + Virology

[< back](#) **Examination category**

Data Element

| | |
|--------------|---------------|
| Form Control | Text Field |
| Data Type | String |
| Header Text | EXAM CATEGORY |

Data Collection Field

| | |
|-------------------------------|--|
| Study Build Policy | Study Build Mandatory Field |
| Repeating Field | No |
| Hidden Field | Yes |
| Protected Field | Yes |
| Study Build Conditional Field | |
| Study Build Alternative Field | |
| Study Build Value Domain | Neurological Exam Category |
| Study Build Value | |
| Study Build Note | |

Rave Global Volume Integrated (GVI)

| | |
|-----------------------------|----------------------|
| Form OID | NE |
| Field OID | EXAMTP |
| Mixed Form Log Field | Yes |
| Format | \$100 |
| Dictionary | |
| SAS Label | Examination Category |
| Integration Field | No |
| Implemented as Postfix Text | |
| Postfix Text | |

SDTM Annotation(s)

Data Collection > CNS > Alzheimer > Neurological Exam > Examination category > T

- + Safety
- + Across Therapeutic Area
- CNS
 - Alzheimer
 - + Alzheimer Disease History
 - + Modified Hachinski Ischemia Scale
 - Neurological Exam
 - Timepoint
 - Was a neurological examination performed?
 - If Yes, date of exam
 - Time of exam
 - Type of neurological examination performed
 - Exam performed?
 - Result
 - Examination category
 - + Schizophrenia
- + Inflammation
- + Metabolism
- + Oncology
- ... Ophthalmology
- + Virology

[← back](#)

Controlled Terminology

Value Domain Attributes

| | |
|---------------------|----------------------------|
| Label | Neurological Exam Category |
| Extensible | No |
| Parent Value Domain | |

Permissible Values

Showing 1 to 5 of 5 Show 50 | [All](#)

<< < 1 > >>

| ↕ CRF Value | ↕ Study Build Policy |
|---------------------------------|--------------------------------------|
| GENERAL NEUROLOGICAL | Study Build Select One Value |
| COGNITIVE/PERCEPTUAL NEUROPATHY | Study Build Select One Value |
| MOTOR NEUROPATHY | Study Build Select One Value |
| SENSORY NEUROPATHY | Study Build Select One Value |
| OTHER | Study Build Select One Value |

| OID | Ordinal | DraftFormName | DraftFormActive | HelpText | IsTemplate | IsSignatureRequired |
|------|---------|-----------------------------------|-----------------|--|------------|---------------------|
| ALZH | 1 | Alzheimer Disease History | TRUE | | FALSE | FALSE |
| MHIS | 2 | Modified Hachinski Ischemia Scale | TRUE | | FALSE | FALSE |
| NE | 3 | Neurological Exam | TRUE | At the Screening visit, enter any findings/conditions on the General Medical History and Baseline Conditions form. After the screening visit, enter any new or worsened findings/conditions on the Adverse Event form. | FALSE | FALSE |

| FormOI | FieldOID | Ordina | DraftFieldNumber | DraftFieldName | DraftFieldActive | VariableOID | DataFormat | DataDictionaryName |
|--------|----------|--------|------------------|----------------|------------------|-------------|---------------|--------------------|
| ALZHX | DIAGD | 1 | | DIAGD | TRUE | DIAGD | dd- MMM- yyyy | |
| ALZHX | DXDTU | 2 | | DXDTU | TRUE | DXDTU | 1 | |
| ALZHX | SCORE | 3 | | SCORE | TRUE | SCORE | 1 | NUMERIC_VALUE_V5 |
| ALZHX | | | | | | | | |
| MHIS | MMHPF | 1 | | MMHPF | TRUE | MMHPF | \$3 | YES_NO |
| MHIS | MMHD | 2 | | MMHD | TRUE | MMHD | dd- MMM- yyyy | |
| MHIS | RAINIT | 3 | | RAINIT | TRUE | RAINIT | \$3 | |
| MHIS | MMHAM1 | 4 | | MMHAM1 | TRUE | MMHAM1 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM2 | 5 | | MMHAM2 | TRUE | MMHAM2 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM3 | 6 | | MMHAM3 | TRUE | MMHAM3 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM4 | 7 | | MMHAM4 | TRUE | MMHAM4 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM5 | 8 | | MMHAM5 | TRUE | MMHAM5 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM6 | 9 | | MMHAM6 | TRUE | MMHAM6 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM7 | 10 | | MMHAM7 | TRUE | MMHAM7 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | MMHAM8 | 11 | | MMHAM8 | TRUE | MMHAM8 | \$11 | PRESENT_ABSENT_V1 |
| MHIS | TTLSCR | 12 | | TTLSCR | TRUE | TTLSCR | 2 | |
| NE | TMPTC | 1 | | TMPTC | TRUE | TMPTC | \$60 | |
| NE | EXAMDN1 | 2 | | EXAMDN1 | TRUE | EXAMDN1 | \$3 | YES_NO_V1 |
| NE | EXMD | 3 | | EXMD | TRUE | EXMD | dd- MMM- yyyy | |
| NE | EXTM | 4 | | EXTM | TRUE | EXTM | HH nn | |
| NE | EXMTH | 5 | | EXMTH | TRUE | EXMTH | \$60 | |
| NE | EXAMDN2 | 6 | | EXAMDN2 | TRUE | EXAMDN2 | \$3 | YES_NO_V1 |
| NE | RSLT | 7 | | RSLT | TRUE | RSLT | \$8 | NORMAL_ABNORMAL_V4 |
| NE | EXAMTP | 8 | | EXAMTP | TRUE | EXAMTP | \$100 | |

Future

Current Roche MDR

Content

- External content
 - SDTM 1.2, SDTMIG 3.1.2
 - NCI Thesaurus, CDISC Controlled Terminology
- Integrated Data Standards, Roche and Genentech
 - Safety and every Roche TA, ~ 2000 data elements
 - Data Collection and Data Tabulation
- Value level metadata
 - Lab measurements (~ 2000), Unit conversions, Questionnaires (~ 150)
- Looking at metadata for
 - SDTM Conformance Checking, Biomarker (HGNC), ...

Unique Value Proposition

Convergence of Standards and Technology

- Coverage and maturity of existing CDISC standards
- Establishment of CDISC standards within the industry
- MDR based standards as a foundation for metadata driven workflow
- Upcoming role of semantic web standards and linked data principles

Roche Group R&D Pipeline



phase I (36 NMEs)

| | | |
|---------------|----------------------------|------------------------|
| RG3639 | dulanermin | cancer |
| RG7256 | BRaf inh(2) | BRAF mutated melanoma |
| RG7112 | MDM2 ant (2) | solid & hem tumors |
| RG7160 | EGFR Mab | solid tumors |
| RG7167 | CIF/MEK inh | solid tumors |
| RG7304 | Raf & MEK dual inh | solid tumors |
| RG7321 | PI3 kinase inh | solid tumors |
| RG7334 | anti-PLGF Mab | solid tumors |
| RG7414 | anti-EGFL7 Mab | solid tumors |
| RG7420 | MEK inh | solid tumors |
| RG7421 | MEK inh | solid tumors |
| RG7422 | PI3 K/mTOR inh | solid&hem tumors |
| RG7440 | AKT inhibitor | solid tumors |
| RG7444 | FGFR3 Mab | multiple myeloma |
| RG7459 | IAP ant (2) | solid tumors& lymphoma |
| RG7593 | CD22 Mab ADC | hem. malignancies |
| RG7594 | antiangiogenic | solid tumors |
| RG7597 | anti-Her3 Mab | m. epithelial tumors |
| RG7686 | anti-glypican Mab | liver cancer |
| CHU | ALK inhibitor | NSCLC |
| CHU | - | solid tumors |
| RG4934 | anti-IL-17 Mab | RA |
| RG7185 | CRTH2 antag | asthma |
| RG7413 | Mab Beta7 | ulcerative colitis |
| RG7432 | nucleoside pol inh (9) | HCV |
| CHU | serine palmitoyltransf inh | HCV |
| RG4929 | 11 beta HSD inh | metabolic diseases |
| RG7236 | Cat S antag | CV risk in CKD |
| RG7273 | ABCA1 inducer | dyslipidemia |
| RG7418 | anti-oxLDL Mab | sec prev CV events |
| RG7685 | GIP/GLP-1 dual ago | type 2 diabetes |
| RG1578 | mGluR2 antag (2) | depression |
| RG1662 | GABA-A a5 inv ago | cogn. disorders |
| RG7166 | triple reuptake inh | depression |
| RG7412 | anti-Abeta Mab | Alzheimer's |
| RG7417 | anti-factor D Mab | geographic atrophy |

phase II (18 NMEs + 8 AIs)

| | | |
|---------------------------|------------------------------|--------------------------------|
| RG1273 | pertuzumab | HER2+ EBC |
| RG1273 | pertuzumab | HER2+ mBC 2 nd line |
| RG3502 | T-DM1 | HER2+ EBC |
| RG3616 | hedgehog path inh | advanced BBC |
| RG3616 | hedgehog path inh | operable BCC |
| RG3638 | MetMab | mNSCLC |
| RG7159 | GA101 anti-CD 20 Mab | NHL & CLL |
| RG7204 | BRaf inh | met. melanoma 2nd/3rd line |
| RG7433 | navitoclax (ABT-263) | sol & hem tumors |
| CHU | topoisomerase I inh | gastric cancer |
| RG3637¹ | lebrikizumab (anti-IL13) | asthma |
| RG4930 | OX40L Mab | asthma |
| RG7415 | rontalizumab (IFN alpha Mab) | SLE |
| RG7416 | anti-LT alpha Mab | RA |
| RG3648 | Xolair | chronic idiopathic urticaria |
| RG7449 | anti-M1 prime Mab | asthma |
| RG3484 | HPV16 | cervical neoplasia |
| RG7128 | nucleoside polymerase inh. | HCV |
| RG7227 | danoprevir (protease inh) | HCV |
| RG1512 | P selectin Mab | CVD |
| RG7201² | SGLT2 inh | type 2 diabetes |
| RG1450 | gantenerumab (A-beta) | Alzheimer's |
| RG1594 | ocrelizumab | RRMS |
| RG3487 | nic alpha7 | Alzheimer's |
| RG7090 | mGluR5 antag (2) | TRD |
| EVO | NMDA receptor antag | TRD |

¹ LIP transition approved

² Ph3 in Japan

³ Complete response in the US

⁴ FPI Jan.2011

phase III (8 NMEs + 25 AIs)

| | | |
|---------------------------|----------------------|--|
| RG105 | Rituxan | NHL fast infusion |
| RG105³ | MabThera | NHL sc formulation |
| RG435 | Avastin | HER2+ BC adj |
| RG435 | Avastin | mBC combo Herceptin 1 st line |
| RG435 | Avastin | NSCLC adj |
| RG435 | Avastin | HER2- BC adj |
| RG435 | Avastin | triple neg BC adj |
| RG435 | Avastin | relapsed ovarian ca |
| RG435 | Avastin | high risk carcinoid |
| RG435 | Avastin | glioblastoma 1 st line |
| RG435 | Avastin | mCRC TML |
| RG435³ | Avastin | mBC 2 nd line |
| RG597 | Herceptin | HER2+ BC sub cut. |
| RG597 | Herceptin | HER2+ adj BC (2yrs) |
| RG1273 | pertuzumab | HER2+ mBC 1 st line |
| RG1415 | Tarceva | NSCLC adj |
| RG1415 | Tarceva | NSCLC EGFR mut 1 st line |
| RG3502 | T-DM1 | HER2+ mBC 1 st line |
| RG3502 | T-DM1 | HER2+ advanced mBC |
| RG7159 | GA101 anti-CD 20 Mab | CLL |
| RG7159 | GA101 anti-CD 20 Mab | iNHL |
| RG7204 | BRaf inh | met. melanoma 1st line |
| RG1569 | Actemra | ankylosing spondylitis |
| RG1569 | Actemra | sc formulation RA |
| RG1569 | Actemra | early RA |
| RG1569 | Actemra | RA DMARD IR H2H |
| RG1439 | aleglitazar | CV risk reduction in T2D |
| RG1658 | dalcetrapib | atherosclerosis CV risk red. |
| RG1594⁴ | ocrelizumab | PPMS |
| RG1678 | GRI | schizophrenia negative sympt. |
| RG1678 | GRI | schizophrenia subopt control |
| RG3645 | Lucentis | diabetic macular edema |
| RG3645 | Lucentis | AMD high dose |

Registration (6 AIs)

| | | |
|----------------|----------------|---------------------------------------|
| RG435* | Avastin | ovarian cancer 1 st line |
| RG435* | Avastin | mBC combo Xeloda 1 st line |
| RG1415* | Tarceva | NSCLC EGFR mut 1 st line |
| RG105** | Rituxan | ANCA assoc vascul |
| RG1569 | Actemra | sJIA |
| CHU | EPOCH | chemo induced anemia |

* in the EU

** in the US

| | |
|---------------|---|
| | NME |
| | Additional Indication |
| | Oncology |
| | Inflammation/Immunology |
| | Virology |
| | Metabolic/Cardiovascular |
| | CNS |
| | Ophthalmology |
| | Others |
| RG-No | Roche Genentech managed |
| CHU | Chugai managed |
| EVO | Evotec |
| RG105 | MabThera is branded as Rituxan in US and Japan |
| RG1569 | Actemra is branded as RoActemra in EU |

Biometrics Metadata Repository


Transforming Drug Development



242
votes




- § To register and manage metadata for intelligent use during the design, collection, analysis and submission of our data to regulatory authorities.
- § To build up a rich knowledge-base over time that includes clear and consistent definitions of all of the concepts we use and how they relate to each other.
- § To accelerate the adoption of industry and internal standards.




Metadata Repository

Information Architecture



Information Standards and Governance

Metadata Driven Workflow



Roche Smarter Information Management (SIM)

Key Objectives 2013 for the Roche Data Standards Office

- Refactor current MDR
 - Model driven applications
- Capture study level metadata
 - Needed for metadata driven workflow
- Metadata driven EDC build
 - Based on Trial Design Model and Schedule of Assessments
- Metadata driven SDTM transformations
 - Code generator
 - Unit test generator
 - Conformance check generator